AARD · NASDAQ · Biotechnology

Aardvark Therapeutics (AARD)

Develops gut-restricted oral programs for hunger-associated conditions and obesity.

$5.75
After-hours close+0.05 (+0.88%)
At close$5.70(+2.33%)

Something off on this page? Send us feedback.

Next report
Nov 12, 26
estimated · in 51 days
EPS estimate
−$0.74
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.44−$0.71−$0.66−$0.75−$0.81−$0.99−$0.66Pending
Estimate−$0.41−$0.67−$0.60−$0.80−$0.83−$0.88−$0.87−$0.74
Surprise−6.1%−5.4%−10.0%+6.1%+2.1%−12.9%+24.5%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2028−$1.01
Sep 2028−$0.94
Jun 2028−$0.82
Mar 2028−$0.73
Dec 2027−$0.51
Sep 2027−$0.53
Jun 2027−$0.61
Mar 2027−$0.69
Dec 2026−$0.72
Nov 2026−$0.74
Aug 2026−$0.87−$0.66+24.5%
May 2026−$0.88−$0.99−12.9%
Mar 2026−$0.83−$0.81+2.1%
Nov 2025−$0.80−$0.75+6.1%
Aug 2025
May 2025
Mar 2025
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023

The latest year is open to everyone — the 8 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2028−$1.01$51.2M
Sep 2028−$0.94$34.4M
Jun 2028−$0.82$14.7M
Mar 2028−$0.73$0
Dec 2027−$0.51$0
Sep 2027−$0.53$0
Jun 2027−$0.61$0
Mar 2027−$0.69$0
Dec 2026−$0.72$0
Nov 12, 2026−$0.74$0
Aug 11, 2026−$0.87−$0.66+24.5%−8.6%
May 7, 2026−$0.88−$0.99−12.9%−4.9%
Mar 23, 2026−$0.83−$0.81+2.1%−7.4%
Nov 13, 2025−$0.80−$0.75+6.1%+1.2%
Aug 13, 2025
May 14, 2025
Mar 31, 2025
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023

The latest year is open to everyone — the 8 quarters behind it read with an account.